Answers are grounded in this paper and cite their sources.
Objective: Remission Rate of Graves' disease (GD) by Anti-thyroid Drugs (ATD) remains around 50% and renovated ATD is not expected soon.As GD is an autoimmune disease associated with Anti-TSH receptor Auto-antibodies (TRAb) and blood TRAb levels presumably reflect immune dysregulation, better practice of ATD therapy could be worked out using TRAb.Methods: 101 patients were treated with ATD in a titration regimen.Their serum TRAb levels were serially measured by a 2 nd generation assay (DYNO test TRAK TM human kit), henceforth designated as hTRAb levels.ATD was continued until the hTRAb levels become undetectable (<1.0 IU/L) consecutively twice (Target A) or reducing in gray-zone (1.0-1.5 IU/L) (Target B).Remission rates, defined by no relapse within-one-year post-ATD, were assessed in patients having attained Target A or Target B. Time Courses (TCs) of hTRAb levels were drawn.Relations of TC patterns and outcomes were sought.Results: The relapse-free remission rate of patients having attained Target A (N=41) among those having attained Target A with or without relapse (N=52) was 78.8 %.The relapse-free remission rate of patients having attained either Target A or Target B (N=52) in the total patients was 51.5 %.Remission was associated with four TC patterns; throughout undetectable levels, gradual reducing and converging to undetectable levels twice, reducing and converging in gray-zone levels, and one or two flair-ups in gradually reducing levels.Conclusion: Until better biomarkers reflecting altered immune status become available, outcomes of GD can be predicted by serially measured TRAb levels during ATD treatment.
No takes yet. Share an insight, caveat, or question.
Tetu Yamamoto (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: